Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RECLAIM-HP Phase 3 study of encaleret in chronic hypoparathyroidism
jRCT2031260613Phase 3Recruiting
- Sponsor
- Calcilytix Therapeutics
- Start
- Oct 2026
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of encaleret in chronic hypoparathyroidism (3 arms), sponsored by Calcilytix Therapeutics. Primary endpoint: Number of responders who achieve both albumin-corrected blood calcium and 24-hour urine calcium within the protocol-defined target range. Started Oct 2026; status: recruiting.
02
Drugs
encaleret
03
Conditions
chronic hypoparathyroidism
Beyond the preview
Go deeper on jRCT2031260613.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260613.